Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to $4.1 million.

  • Rani Therapeutics Holdings' Cash & Equivalents fell 310.97% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 310.97%. This contributed to the annual value of $3.8 million for FY2024, which is 3584.58% down from last year.
  • Per Rani Therapeutics Holdings' latest filing, its Cash & Equivalents stood at $4.1 million for Q3 2025, which was down 310.97% from $10.2 million recorded in Q2 2025.
  • Over the past 5 years, Rani Therapeutics Holdings' Cash & Equivalents peaked at $129.7 million during Q3 2021, and registered a low of $3.8 million during Q4 2024.
  • Over the past 5 years, Rani Therapeutics Holdings' median Cash & Equivalents value was $13.1 million (recorded in 2025), while the average stood at $36.8 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 77561.9% in 2021, then tumbled by 9222.89% in 2023.
  • Quarter analysis of 5 years shows Rani Therapeutics Holdings' Cash & Equivalents stood at $117.5 million in 2021, then tumbled by 77.01% to $27.0 million in 2022, then tumbled by 78.29% to $5.9 million in 2023, then tumbled by 35.85% to $3.8 million in 2024, then rose by 10.15% to $4.1 million in 2025.
  • Its Cash & Equivalents stands at $4.1 million for Q3 2025, versus $10.2 million for Q2 2025 and $15.9 million for Q1 2025.